Opinion|Videos|July 8, 2024
Switching Treatments in Spinal Muscular Atrophy
Key opinion leaders share their strategies for discussing potential changes in therapy and transitioning between treatments with patients, emphasizing the importance of reassuring patients that such changes are intended to provide long-term benefits for managing their spinal muscular atrophy.
Advertisement
Episodes in this series
- How would you approach a discussion about a change in therapy?
Advertisement
Related to this article
Postmarketing reports of product-related insertional oncogenesis involving GLI1 have prompted an FDA investigation into malignancy risk with SMA gene therapy, onasemnogene abeparvovec.
Interim phase 1b data showed cizutamig produced rapid, sustained improvement in generalized myasthenia gravis with no cases of cytokine release syndrome.
Catch up on any of the neurology headlines you may have missed in October 2026, compiled into 1 place by the NeurologyLive® team.
Here's some of what is coming soon to NeurologyLive® this week.
Newly presented biomarker and clinical findings from the phase 2b PARADIGM trial of PrimeC informed the design of the global phase 3 PARAGON trial in ALS.
Two-year data from the phase 2 DAZALS trial showed a lower risk of death with dazucorilant 300 mg/day vs placebo in ALS, although the study did not meet its functional primary end point.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 6, 2026.
Servier reported that sevasemten did not meet its primary or secondary end points in the pivotal GRAND CANYON trial for Becker muscular dystrophy.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention
2
FDA Investigates Confirmed Insertional Oncogenesis With Spinal Muscular Atrophy Gene Therapy
3
Examining High-Dose Influenza Vaccination and Alzheimer Disease Risk
4
New CTE Prevalence Estimate Underscores Push for Diagnosis Living Patients
5